Phase I Data on SAHA, a Histone Deacetylase Inhibitor
TARRYTOWN, New York-Aton Pharma, Inc and its collaborators presented phase I data on its oral histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) at the 14th Annual EORTC/NCI/AACR symposium, held in Frankfurt, Germany. The trial of patients with refractory solid tumors, lymphomas, and leukemias, being conducted with researchers at Memorial Sloan-Ket-tering Cancer Center, defined a safe daily oral dosing regimen.
TARRYTOWN, New YorkAton Pharma, Inc and its collaborators presented phase I data on its oral histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) at the 14th Annual EORTC/NCI/AACR symposium, held in Frankfurt, Germany. The trial of patients with refractory solid tumors, lymphomas, and leukemias, being conducted with researchers at Memorial Sloan-Ket-tering Cancer Center, defined a safe daily oral dosing regimen.
Evidence of antitumor activity was also observed. Of the 28 patients with solid tumors, one (larynx cancer) had a partial response, two (renal cell cancer and transitional cell cancer) had reduction in measurable disease, and one (papillary thyroid cancer) had stable disease for more than 2 months.
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
